Late next year, dermatologists will be able to submit a biopsy for genetic analysis and Ampel will then identify the best drugs for treatment.

AMPEL BioSolutions today announces a breakthrough in precision and personalized medicine that could revolutionize the way doctors treat inflammatory skin diseases.